CD274 and urothelial carcinoma: Since the patient presented a primary resistance to polychemotheray, an acquired resistance to osimertinib after five months of treatment, a positive PDL1 expression, and an analogy of therapeutic management of urothelial carcinoma, pembrolizumab, a check-point inhibitor, was introduced as third-line therapy.